Statement on high-altitude illnesses. An Advisory Committee Statement (ACS).
D000086:Acetazolamide / Q000627:therapeutic use; D000208:Acute Disease; D000532:Altitude Sickness / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D002170:Canada; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D008704:Methazolamide / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D012893:Sleep Wake Disorders / Q000209:etiology; D013450:Sulfones / Q000627:therapeutic use; D014195:Travel
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D003907:Dexamethasone; D000068677:Sildenafil Citrate; D009543:Nifedipine; D000086:Acetazolamide; D008704:Methazolamide